State of the art: The hypereosinophilic syndromes

Blood Reviews

Volumn 5, Issue 1, 1991, Pages 29-37

  Liesveld, J L ^a   Abboud, C N ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOKINE; HYDROCORTISONE; HYDROXYUREA; INTERLEUKIN 1;

HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; REVIEW; T LYMPHOCYTE ACTIVATION;

EOSINOPHILIA; HUMAN; INTERLEUKINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SYNDROME; T-LYMPHOCYTES;

EID: 0025973723     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-960X(91)90005-W     Document Type: Article

References (103)

1. Current concepts. Eosinophil function
2. A case of the eosinophilia-myalgia syndrome associated with use of an L-tryptophan product
3. Eosinophilopoiesis
4. Eosinophils: morphology, production, chemistry and function
5. Synthesis and secretion of eosinophil granule substances
6. Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium
7. Hemopoietins for eosinophils: Glycoprotein hormones that regulate the development of inflammation in eosinophilia-associated disease
8. Platelet activating factor: A potent chemotactic and chemokinetics factor for human eosinophils
9. Recombinant human interleukin 5 is a selective eosinophil chemoattractant
10. Characterization of a factor produced by human T-cell clones exhibiting eosinophil-activating and burst-promoting activities
11. Humoral regulation of eosinophilopoiesis in vitro: analysis of the targets of interleukin-3, granulocyte/macrophage colony-stimulating factor (GM-CSF), and interleukin 5
12. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GM-CSF
13. Human eosinophil hematopoiesis studies in vitro by means of murine eosinophil differentiation factor (IL-5): Production of functionally active eosinophils from normal human bone marrow
14. Synergism among interleukin 1, interleukin 3, and interleukin 5 in the production of eosinophils from primitive hemopoietic stem cells
15. Effect of human recombinant interleukin 5 and G-CSF on eosinophil colony formation
16. Functions of the eosinophil leukocyte
17. The hypereosinophilic syndrome: analysis of 14 cases with review of the literature
18. Altered density, metabolism, and surface receptors of eosinophils in eosinophilia
19. Fegamma and CD11/CD18 receptor expression on normal density and low density human eosinophils
20. Enhanced helminthotoxic capacity of eosinophils from patients with eosinophilia
21. Heterogeneity of human peripheral blood eosinophils: Variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophila
22. Hypereosinophilic syndrome human eosinophil degranulation induced by soluble and particulate stimuli
23. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony stimulating factor
24. Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts
25. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3
26. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor
27. Recombinant human interleukin 5 is a selective activator of human eosinophil function
28. Stimulation of eosinophil adherence to human vascular endothelial cells in vitro by platelet-activating factor
29. Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor
30. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome
31. Peripheral blood myeloid progenitor cell cultures in patients with hypereosinophilic syndrome (CFU-Eos in hypereosinophilic syndrome)
32. In vivo administration of antibody to interleukin-5 inhibits increased generation of eosinophils and their progenitors in bone marrow of parasitized mice
33. Mechanism of eosinophilia II. Role of the lymphocyte
34. Mature human eosinophils have the capacity to express HLA-DR
35. Specific production of eosinophil colony stimulating factor from sensitized T-cells from a patient with allergic eosinophilia
36. Interleukin 2 stimulates the T cells from patients with eosinophilia to produce CFU-Eo growth stimulating factor
37. T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation
38. T lymphocyte control of human eosinophilic granulopoiesis
39. The appearance of hypodense eosinophils during interleukin-2 treatment
40. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients
41. Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells
42. Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution
43. Interleukin-2-dependent release of interleukin-3 activity by T4+ human T-cell clones
44. Role of IL-5 in IL-2 induced eosinophilia: in vivo and in vitro expression of IL-5 mRNA by IL-2
45. The biological role of interleukin 5
46. Interleukin 5 is a differentiation factor for cytotoxic T lymphocytes
47. Interleukin-5 induces maturation but not class switching of surface IgA-positive B cells into IgA-secreting cells
48. T-cell replacing factor (interleukin-5) induces expression of interleukin 2 receptors on murine splenic B cells
49. Interleukin 5 enhances interleukin-2-mediated lymphokine-activated killer activity
50. Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemia with a Del (5q)
51. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice
52. Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni
53. Regulation of parasite-induced eosinophilia: selectively increased interleukin-5 production in helminth-infected patients
54. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations
55. The idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations
56. The cardiotoxicity of eosinophils
57. Relation between eosinophilia and endomyocardial disease
58. Two-dimensional and doppler echocardiographic findings in hypereosinophilic syndrome
59. Two-dimensional echocardiographic assessment of the idiopathic hypereosinophilic syndrome: anatomic basis of mitral regurgitation and peripheral embolization
60. Aortic and mitral valve replacement in idiopathic hypereosinophilic syndrome
61. Chronic eosinophilic pneumonia; a report of 19 cases and a review of the literature
62. Dermatologic manifestations of the hypereosinophilic syndrome
63. Aquagenic pruritis associated with the idiopathic hypereosinophilic syndrome
64. Hypereosinophilia and recurrent angioneurotic edema in a 2 1/2-year-old girl
65. PUVA therapy in the treatment of skin lesions of the hypereosinophilic syndrome
66. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome
67. Eosinophilic meningitis and the hypereosinophilic syndrome. Case report and review of the literature
68. Reversible dementia with idiopathic hypereosinophilic syndrome
69. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome
70. Polyneuropathy in hypereosinophilic syndrome
71. Neuropathy in the hypereosinophilic syndrome
72. Molecular cloning of the human eosinophil-derived neurotoxin. A member of the ribonuclease gene family
73. Eosinophilic colitis as a complication of the hypereosinophilic syndrome
74. Idiopathic hypereosinophilic syndrome with polymyositis
75. The hypereosinophilic syndromes
76. Pulmonary carcinoma with eosinophilia: demonstration of a tumor-derived eosinophilopoeitic factor
77. Paraneoplastic eosinophilia: report of a case with in vitro studies of hemopoiesis
78. Malignant fibrous histiocytoma associated with peripheral blood eosinophilia: in vitro studies demonstrating tumorderived eosinophilopoietic activity
79. Idiopathic hypereosinophilic syndrome progressing to acute myelomonocytic leukemia with chloromas
80. Hypereosinophilic syndrome and plasmacytoma: report of a case and review of the literature
81. The hypereosinophilic syndrome in acute lymphocytic leukemia
82. A case of acute myelogenous leukaemia associated with eosinophilia: cytogenetic study of eosinophilic colonies showing the origin of the normal clone
83. Calla-positive acute leukemia with t(5q;14q) translocation and hypereosinophilia—a unique entity?
84. Abnormalities of chromosome 16 in association with acute myelomonocytic leukemia and dysplastic bone marrow eosinophils
85. Trisomy 22—A new abnormality found in acute leukemia characterized by eosinophilia and monocytoid blasts expressing immature differentiation antigens
86. Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils; a nonrandom association
87. Acute eosinophilic leukemia with a translocation (10p+;11q−)
88. Chromosome and cell culture studies in eosinophilic leukaemia
89. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan
90. Eosinophilia-myalgia syndrome: results of national surveillance
91. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use
92. Analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome
93. Scleroderma, fascitis, and eosinophilia associated with the ingestion of tryptophan
94. Therapy of the hypereosinophilic syndrome
95. Management of the idiopathic hypereosinophilic syndrome
96. Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy
97. Interleukin 5 activity in sera from patients with eosinophilia
98. Response to vincristine treatment in a case of idiopathic hypereosinophic syndrome with multiple clinical manifestations
99. Effective therapy for a severe case of the idiopathic hypereosinophilic syndrome
100. Hypereosinophilic syndrome with multiple organ dysfunctions treated by allogeneic bone marrow transplantation
101. Alfa-interferon in a case of hypereosinophilic syndrome
102. Autocrine growth of a human T-cell line is inhibited by cyclosporin A
103. Mechanism of T cell activation: Role and functional relationship of HLA-DR antigens and interleukins